Abstract CT041: Identification of gene signatures associated with response in a Phase II trial of entinostat (ENT) plus pembrolizumab (PEMBRO) in non-small cell lung cancer (NSCLC) patients whose disease has progressed on or after anti-PD-(L)1 therapy

Author(s):  
Peter Ordentlich ◽  
Lei Wang ◽  
David Tamang ◽  
Amy H. Sullivan ◽  
Sally E. Church ◽  
...  
Sign in / Sign up

Export Citation Format

Share Document